|
1
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: a representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar
|
|
3
|
Dowling RJ, Niraula S, Stambolic V and
Goodwin PJ: Metformin in cancer: translational challenges. J Mol
Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nair V, Pathi S, Jutooru I, et al:
Metformin inhibits pancreatic cancer cell and tumor growth and
downregulates Sp transcription factors. Carcinogenesis.
34:2870–2879. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akinyeke T, Matsumura S, Wang X, et al:
Metformin targets c-MYC oncogene to prevent prostate cancer.
Carcinogenesis. 34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alimova IN, Liu B, Fan Z, et al: Metformin
inhibits breast cancer cell growth, colony formation and induces
cell cycle arrest in vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato K, Gong J, Iwama H, et al: The
antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrushev B, Tomuleasa C, Soritau O, et
al: Metformin plus PIAF combination chemotherapy for hepatocellular
carcinoma. Exp Oncol. 34:17–24. 2012.PubMed/NCBI
|
|
9
|
Ashinuma H, Takiguchi Y, Kitazono S, et
al: Antiproliferative action of metformin in human lung cancer cell
lines. Oncol Rep. 28:8–14. 2012.
|
|
10
|
Chen G, Xu S, Renko K and Derwahl M:
Metformin inhibits growth of thyroid carcinoma cells, suppresses
self-renewal of derived cancer stem cells, and potentiates the
effect of chemotherapeutic agents. J Clin Endocrinol Metab.
97:E510–E520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaiteerakij R, Yang JD, Harmsen WS, et
al: Risk factors for intrahepatic cholangiocarcinoma: association
between metformin use and reduced cancer risk. Hepatology.
57:648–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar
|
|
14
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaib YH, Davila JA, McGlynn K and
El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in
the United States: a true increase? J Hepatol. 40:472–477. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaudhary SC, Kurundkar D, Elmets CA,
Kopelovich L and Athar M: Metformin, an antidiabetic agent reduces
growth of cutaneous squamous cell carcinoma by targeting mTOR
signaling pathway. Photochem Photobiol. 88:1149–1156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin B, Kolluri SK, Lin F, et al:
Conversion of Bcl-2 from protector to killer by interaction with
nuclear orphan receptor Nur77/TR3. Cell. 116:527–540. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee D, Do IG, Choi K, et al: The
expression of phospho-AKT1 and phospho-MTOR is associated with a
favorable prognosis independent of PTEN expression in intrahepatic
cholangiocarcinomas. Mod Pathol. 25:131–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chung JY, Hong SM, Choi BY, Cho H, Yu E
and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and
PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res.
15:660–667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu B, Fan Z, Edgerton SM, et al:
Metformin induces unique biological and molecular responses in
triple negative breast cancer cells. Cell Cycle. 8:2031–2040. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how
mutations can result in therapy resistance and how to overcome
resistance. Oncotarget. 3:1068–1111. 2012.PubMed/NCBI
|
|
24
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Mutations and deregulation of Ras/Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
Oncotarget. 3:954–987. 2012.PubMed/NCBI
|
|
25
|
Takiyama Y, Harumi T, Watanabe J, et al:
Tubular injury in a rat model of type 2 diabetes is prevented by
metformin: a possible role of HIF-1alpha expression and oxygen
metabolism. Diabetes. 60:981–992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan
E and Oktay TM: Use of oral antidiabetic drugs (metformin and
pioglitazone) in diabetic patients with breast cancer: how does it
affect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev.
13:5143–5148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zannella VE, Pra AD, Muaddi H, et al:
Reprogramming metabolism with metformin improves tumor oxygenation
and radiotherapy response. Clin Cancer Res. 19:6741–6750. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheng B, Liu J and Li GH: Metformin
preconditioning protects Daphnia pulex from lethal hypoxic
insult involving AMPK, HIF and mTOR signaling. Comp Biochem Physiol
B Biochem Mol Biol. 163:51–58. 2012.PubMed/NCBI
|
|
29
|
Li Y and Ye D: Cancer therapy by targeting
hypoxia-inducible factor-1. Curr Cancer Drug Targets. 10:782–796.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rho JK, Choi YJ, Lee JK, et al: Gefitinib
circumvents hypoxia-induced drug resistance by the modulation of
HIF-1α. Oncol Rep. 21:801–807. 2009.PubMed/NCBI
|
|
31
|
Huang C, Xu D, Xia Q, Wang P, Rong C and
Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of
human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol.
64:1741–1750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu H, Luo SF, Wang J, et al: Effect of
environmental factors on chemoresistance of HepG2 cells by
regulating hypoxia-inducible factor-1alpha. Chin Med J (Engl).
125:1095–1103. 2012.PubMed/NCBI
|
|
33
|
Ding Z, Yang L, Xie X, et al: Expression
and significance of hypoxia-inducible factor-1 alpha and
MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J
Cancer Res Clin Oncol. 136:1697–1707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li DW, Dong P, Wang F, Chen XW, Xu CZ and
Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer
cells via hypoxia-inducible factor-1alpha. Asian Pac J Cancer Prev.
14:4853–4858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen M, Huang SL, Zhang XQ, et al:
Reversal effects of pantoprazole on multidrug resistance in human
gastric adenocarcinoma cells by down-regulating the
V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro
and in vivo. J Cell Biochem. 113:2474–2487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Woo HY and Heo J: Sorafenib in liver
cancer. Expert Opin Pharmacother. 13:1059–1067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eguchi R, Fujimori Y, Takeda H, et al:
Arsenic trioxide induces apoptosis through JNK and ERK in human
mesothelioma cells. J Cell Physiol. 226:762–768. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petit A, Delaune A, Falluel-Morel A, et
al: Importance of ERK activation in
As2O3-induced differentiation and
promyelocytic leukemia nuclear bodies formation in neuroblastoma
cells. Pharmacol Res. 77:11–21. 2013.
|
